Details of the Drug Combination

General Information of Drug Combination (ID: DC0WG15)

Drug Combination Name
Ginsenoside Rb1 Mefloquine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Ginsenoside Rb1   DMF70AB Mefloquine   DMWT905
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 2.69
Bliss Independence Score: 2.69
Loewe Additivity Score: 3.48
LHighest Single Agent (HSA) Score: 3.54

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Ginsenoside Rb1 Interacts with 23 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-glucosidase (bglA) DEUO7V8 A0A509DD13_9STRE Metabolism [6]
Beta-glucosidase (bglA) DE4LKZ9 A0A3D1ZWL4_9BIFI Metabolism [6]
Beta-glucosidase (bglA) DEM6GYO A0A351PC96_9FIRM Metabolism [7], [6]
Beta-glucosidase (bglA) DE9N4OU C6WCL5_ACTMD Metabolism [8]
Beta-glucosidase (bglA) DERPJZ6 A0A4Q4LS82_BIFAN Metabolism [9]
Beta-glucosidase (bglA) DEVLXCG R7LVY8_9FUSO Metabolism [6]
Beta-glucosidase (bglA) DEUQTKA A0A249DCH3_LACRH Metabolism [9]
Beta-glucosidase (bglA) DEXRUS1 A0A267WL33_9BIFI Metabolism [10]
Beta-glucosidase (bglA) DERX7ML A0A3B8TKP6_9FIRM Metabolism [10]
Beta-glucosidase (bglA) DEOHI3U A0A0P0FEZ9_BACT4 Metabolism [10]
Beta-glucosidase (bglA) DE46IH1 A0A1T4QCU7_9PROT Metabolism [11]
Beta-glucosidase (bglA) DEE8WXK A0A076JJU4_BIFAD Metabolism [10]
Beta-glucosidase (bglA) DECBSVP A0A126SWK8_9BIFI Metabolism [10]
Beta-glucosidase (bglA) DEAVLU4 BGLFU_BIFBR Metabolism [10]
Beta-glucosidase (bglA) DEPBQES BGLS_BUTFI Metabolism [10]
Beta-glucosidase (bglA) DEGVUWH A0A174JG46_9FIRM Metabolism [10]
Beta-glucosidase (bglA) DEE8RS0 A0A174GPV4_9FIRM Metabolism [10]
Beta-glucosidase (bglA) DEC0M8H A0A174ZK85_9FIRM Metabolism [10]
Beta-glucosidase (bglA) DE2OMS0 A0A173UNF6_9FIRM Metabolism [10]
Beta-glucosidase (bglA) DEPUNVR A0A395V8H8_9FIRM Metabolism [10]
Beta-glucosidase (bglA) DEX7SAW A0A3R6A2W5_9FIRM Metabolism [10]
Beta-glucosidase (bglA) DEE3I1P A0A412BAD0_9FIRM Metabolism [10]
Beta-glucosidase (bglA) DEASJG5 A5ZMW4_9FIRM Metabolism [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DME(s)
Ginsenoside Rb1 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily E member 1 (KCNE1) OTZNQUW9 KCNE1_HUMAN Increases Expression [12]
------------------------------------------------------------------------------------
Indication(s) of Mefloquine
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [4]
Severe acute respiratory syndrome (SARS) 1D65 Preclinical [4]
Progressive multifocal leukoencephalopathy 8A45.02 Investigative [5]
Mefloquine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Plasmodium 80S ribosome (Malaria 80S) TTT28H3 NOUNIPROTAC Binder [13]
------------------------------------------------------------------------------------
Mefloquine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]
------------------------------------------------------------------------------------
Mefloquine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [15]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 019578
3 ClinicalTrials.gov (NCT04347031) An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19. U.S. National Institutes of Health.
4 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
5 Mefloquine FDA Label
6 Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
7 Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol. 1998 Oct;50(10):1155-60.
8 Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
9 Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
10 Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
11 Genus Enhydrobacter Staley et al. 1987 should be recognized as a member of the family Rhodospirillaceae within the class Alphaproteobacteria. Microbiol Immunol. 2012 Jan;56(1):21-6.
12 Ginsenosides may enhance the functionality of human embryonic stem cell-derived cardiomyocytes in vitro. Reprod Sci. 2014 Oct;21(10):1312-8. doi: 10.1177/1933719114525269. Epub 2014 Mar 10.
13 An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14.
14 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
15 Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol. 2000 Oct;52(10):1265-9.